Question Bank › Conversion calendar in hand

Conversion calendar in hand

Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured

Calls Tested
443
Answered YES
6
Hit Rate
1.4%
rare by design

Intra-Cellular Therapies, Inc. (ITCI) — this company's answers

NO on the Q4 2017 call 2018-03-01 D
The model's full reasoning — Q4 2017 call → NOThe question asks whether management lays out a timetable of specific conversions — identified pieces of business that are already secured or already in motion, each attached to an at-least-approximate time frame in which it starts contributing — so that the forward story reads as a schedule of things turning on, rather than as hopes about demand. Let me review the transcript for what management says about the next four or so quarters. Key forward-looking items mentioned: 1. NDA submission for lumateperone for schizophrenia by mid-2018 — this is a regulatory filing, not a "conversion" of secured business. It's contingent on FDA approval. 2. Pre-NDA meeting with FDA later this month (March 2018) — again regulatory. 3. Bipolar depression studies: Study 401 topline in second half 2018, Study 404 in 2019 — these are clinical trial results, not secured business. 4. Agitation in Alzheimer's disease: interim analysis in second half 2018 — clinical trial. 5. ITI-214 Phase 1/2 in Parkinson's: topline results second half 2018 — clinical trial. 6. ITI-214 heart failure study starting this month — clinical trial. 7. ITI-333 preclinical, entering clinic next year — not secured. 8. Commercial launch preparation for lumateperone — but no approval yet. The question asks about "conversions" — identified pieces of business that are already secured or already in motion, each attached to a time frame in which it starts contributing. This is about revenue-generating business, like contracts, orders, facilities opening, customers going live, etc. In this case, the company is a biotech with no approved products. All the forward items are clinical trials, regulatory filings, and development milestones. None of these are "secured business" — they are all contingent on clinical trial outcomes, FDA approvals, etc. There is no revenue yet. The company is pre-commercial. The forward story is about clinical development milestones, not about secured business converting to revenue. The items are all contingent on approvals, trial results, etc. There's no "already secured" business. Therefore, the answer is NO.

← Back to the full ITCI analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, when management talks about the company's NEXT FOUR OR SO QUARTERS, does it lay out a TIMETABLE OF SPECIFIC CONVERSIONS \u2014 identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing \u2014 so that the forward story reads as a schedule of things turning on, rather than as hopes about demand?\n\nAnswer YES when management's own words convey BOTH of the following as one coherent forward account, in whatever form fits the business:\n\n(1) THE ITEMS ON THE TIMETABLE ARE ALREADY REAL. Management identifies concrete business whose existence is no longer in question \u2014 already won, signed, awarded, ordered, booked, contracted, built, launched, closed, or already ramping \u2014 in whatever form fits the industry: contracted work or orders scheduled for delivery; a facility, capacity, product, service, or location recently completed or opening on a stated timetable and now filling; customers or programs already signed that go live or scale on a described schedule; an acquisition or expansion already closed whose contribution phases in; committed volumes stepping up on agreed dates. One substantial item or several smaller ones together both count. Items still being pursued, negotiated, piloted without commitment, or awaiting approvals, financing, or customer decisions do NOT count toward the timetable.\n\n(2) MANAGEMENT ATTACHES TIMING AND TREATS THE SCHEDULE AS THE FORWARD STORY. Management gives each identified item an at-least-rough time anchor within roughly the coming year (this quarter, next quarter, by mid-year, second half, a named month or season) and presents working through this sequence \u2014 starting, ramping, delivering, onboarding, filling \u2014 as the main driver of where the company's results go from here, conveying directly or plainly in substance that the period just reported does not yet meaningfully reflect these contributions, so today's numbers describe the company before the scheduled conversions land.\n\nAnswer NO if the forward discussion rests mainly on demand strength, market conditions, pipeline, opportunities being pursued, or general optimism, with no dated schedule of secured items. NO if the timetable consists of routine, ordinary-course activity at the company's usual scale \u2014 the normal cadence of openings, orders, or seasonal work it always has \u2014 that management does not present as stepping the company beyond its current level. NO if the named items are contingent on approvals, financing, negotiations, or decisions not yet made, or if the only timing given is vague ('over time', 'in the coming years', 'eventually'). NO if the scheduled items' contributions are already substantially reflected in the reported results. NO if management is chiefly explaining delays, slippage, cancellations, or problems with a previously described schedule. NO if the schedule is assembled only in an analyst's question or model that management does not itself adopt.\n\nUse only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ESEA Euroseas Ltd. Q4 2022 2023-02-15 C+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A

How the model reasoned

CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.

More from the question bank

Betting on a customer they cannot yet nameGround-level proof points accumulatingWinning more per swing than they used to — aFresh order-of-magnitude reference changeThis quarter could not have been described lOutside actors already movingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.